Clinical Usefulness of Prostate-specific Membrane Antigen-ligand Positron Emission Tomography/Computed Tomography for the Detection of Prostate Cancer Biochemical Recurrence after Primary Radiation Therapy in Patients with Prostate-specific Antigen Below the Phoenix Threshold: Systematic Review and Meta-analysis.


Journal

Clinical oncology (Royal College of Radiologists (Great Britain))
ISSN: 1433-2981
Titre abrégé: Clin Oncol (R Coll Radiol)
Pays: England
ID NLM: 9002902

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 12 04 2023
revised: 01 07 2023
accepted: 20 09 2023
medline: 20 11 2023
pubmed: 7 10 2023
entrez: 6 10 2023
Statut: ppublish

Résumé

After primary radiotherapy, biochemical recurrence is defined according to the Phoenix criteria as a prostate-specific antigen (PSA) value >2 ng/ml relative to the nadir. Several studies have shown that prostate-specific membrane antigen (PSMA)-ligand positron emission tomography/computed tomography (PET/CT) can help in detecting recurrence in patients with low PSA values. This study aimed to assess the detection rate and patterns of PSMA-ligand PET/CT uptake in patients with suspected biochemical recurrence after primary radiotherapy and with PSA levels below the Phoenix threshold. The meta-analysis was carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Articles providing data on patients with suspected prostate cancer recurrence after primary radiotherapy with a PSA value below the Phoenix threshold and who underwent PSMA-ligand PET/CT were included. Quality assessment was carried out using the Quality Assessment of Diagnostic Accuracy Studies-2 tool (QUADAS-2). In total, five studies were included, recruiting 909 patients (202 with PSA ≤2 ng/ml). The PSMA-ligand detection rate in the patients with ≤2 ng/ml ranged from 66 to 83%. The most frequent source of PSMA-ligand PET/CT uptake was local recurrence, followed by lymph node metastasis and bone metastasis. PSMA-ligand PET/CT uptake due to local-only recurrence was more likely in patients with PSA ≤2 ng/ml compared with PSA > 2 ng/ml: risk ratio 0.72 (95% confidence interval 0.58-0.89), P = 0.003. No significant differences were observed in the detection of PSMA-ligand uptake in other areas. Limitations include a lack of biopsy confirmation, cohort reports with small sample sizes and a potentially high risk of bias. A significant detection of PSMA-ligand-avid disease was observed in patients with PSA levels below the Phoenix threshold. There was a higher likelihood of detecting local-only uptake when the PSA value was ≤2 ng/ml. The findings suggest that a critical review of the Phoenix criteria may be warranted in the era of PSMA-ligand PET/CT and highlight the need for further prospective trials.

Identifiants

pubmed: 37802722
pii: S0936-6555(23)00333-3
doi: 10.1016/j.clon.2023.09.012
pii:
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77
Ligands 0

Types de publication

Meta-Analysis Systematic Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e676-e688

Informations de copyright

Copyright © 2023. Published by Elsevier Ltd.

Auteurs

J D Subiela (JD)

Department of Urology, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá, Madrid, Spain. Electronic address: jdsubiela@gmail.com.

E Gomis Sellés (E)

Radiation Oncology Department, University Hospital Virgen del Rocío, Biomedical Institute of Seville (IBIS)/CSIC/University of Seville, Seville, Spain.

A Maldonado (A)

Nuclear Medicine and Molecular Imaging Department, University Hospital Quiron-salud Madrid/La Luz Hospital, Madrid, Spain.

F Lopez Campos (F)

Radiation Oncology Department, University Hospital Ramon y Cajal, Madrid, Spain.

J Aumatell Ovide (J)

Department of Urology, Hospital Universitario Rey Juan Carlos, Madrid, Spain.

O Ajuria Illarramendi (O)

Nuclear Medicine Department, University Hospital Ramon y Cajal, Madrid, Spain.

D A González-Padilla (DA)

Department of Urology, Clínica Universidad de Navarra, Madrid, Spain.

P Gajate (P)

Medical Oncology Department, Ramon y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.

L E Ortega Polledo (LE)

Department of Urology, Hospital Universitario Príncipe de Asturias, Universidad de Alcalá, Alcalá de Henares, Spain.

S Alonso Y Gregorio (S)

Institute of Urology, San Francisco de Asís Hospital, Madrid, Spain.

F Guerrero-Ramos (F)

Department of Urology, Hospital Universitario 12 de Octubre, Madrid, Spain.

V Gómez Dos Santos (V)

Department of Urology, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá, Madrid, Spain.

R Rodríguez-Patrón (R)

Department of Urology, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá, Madrid, Spain.

J Calais (J)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.

A U Kishan (AU)

Department of Radiation Oncology and Department of Urology, University of California, Los Angeles, CA, USA.

F J Burgos Revilla (FJ)

Department of Urology, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá, Madrid, Spain.

F Couñago (F)

Department of Radiation Oncology, San Francisco de Asís Hospital, Madrid, Spain; Department of Radiation Oncology, La Milagrosa Hospital, Madrid, Spain; National Chair of Research, GenesisCare, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH